Intrapharm laboratories have announced that a full supply of Inhixa (Enoxaparin Sodium) to the U.K. market is guaranteed. In recent months, the Low Molecular Weight Heparin market (LMWH) has seen considerable supply disruption and volatility, which has placed hospitals and pharmacies in the position of managing scarce supplies.
Intrapharm launched Inhixa (Enoxaparin Sodium), the first biosimilar of Enoxaparin Sodium, indicated for VTE prophylaxis and DVT treatment to the U.K. market in September 2017. Inhixa is manufactured in China by Techdow. The Techdow group of companies have been commercially manufacturing Enoxaparin API since 2005 and have full control over their own supply chain.
Inhixa (Enoxaparin Sodium) is available from AAH, Phoenix and Movianto, in 5 presentations, which include 20mg/0.2mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL and 100mg/1mL in packs of 10 prefilled syringes with active needle guard.
Tel: 01234 248632
Fax: 01234 248705
Basic NHS price for packsize 10 preﬁlled syringes with needle guard: 20mg/0.2ml - £16.69; 40mg/0.4ml -£24.22; 60mg/0.6ml -£31.41; 80mg/0.8ml -£44.10; 100mg/1ml -£57.84